Table 2.
Differences in clinical characteristics between the treatment groups at 6 weeks
| Clinical assessments | Difference between groups at 6 week (95% CI) | P-value |
|---|---|---|
| HAMD-24 | – | – |
| Anxiety/somatization | –0.156(–1.480–1.167) | 0.815 |
| Weight loss | –0.027(–0.347–0.293) | 0.868 |
| Cognitive impairment | 0.895(0.251–1.539) | 0.007 |
| Circadian fluctuations | 0.06(–0.208–0.328) | 0.657 |
| Retardation | 1.085 (0.081–2.089) | 0.035 |
| Sleep disturbances | 0.592(–0.218–1.401) | 0.15 |
| Hopelessness | 0.814(0.097–1.530) | 0.027 |
| BDI-II | 4.140(–1.247–9.527) | 0.13 |
| Kessler | 2.454(–2.461–7.368) | 0.323 |
| PSQI | 1.496(–0.517–3.51) | 0.143 |
| SCARED | 7.591(–0.556–15.737) | 0.067 |
Results are present as difference (95% CI) of measurement scores based on estimated marginal mean at 6 weeks between intervention groups (Placebo minus LBP). BDI-II: Beck Depression Inventory-II; CI: confidence interval; HAMD-24: Hamilton Depression Rating Scale; Kessler: The Kessler Psychological Distress Scale; PSQI: The Pittsburgh Sleep Quality Index; SCARED: Screen for Child Anxiety-Related Emotional Disorders.